 |  |
Researchers at the Dana-Farber Cancer Institute and MIT have developed a novel ex vivo assay (above) to profile the PD-1 blockade, making it possible to interrogate the tumor immune microenvironment, develop novel therapeutic combinations, and facilitate precision immuno-oncology efforts. The assay is detailed by Jenkins et al in “Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids“, Cancer Discovery doi: 10.1158/2159-8290.CD-17-0833
The ex vivo organotypic tumor spheroid culture system was utilised by Deng et al to show that CDK4/6 inhibition augments the response to PD-1 blockade. The effect was validated in multiple in vivo murine syngeneic models, thereby providing a rationale for combining CDK4/6 inhibitors and immunotherapies. The results are detailed in “CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation”, Cancer Discovery doi: 10.1158/2159-8290.CD-17-0915
Dana-Farber Cancer Institute news release (click here)
The ex vivo organotypic tumor spheroid culture system was utilised by Deng et al to show that CDK4/6 inhibition augments the response to PD-1 blockade. The effect was validated in multiple in vivo murine syngeneic models, thereby providing a rationale for combining CDK4/6 inhibitors and immunotherapies. The results are detailed in “CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation”, Cancer Discovery doi: 10.1158/2159-8290.CD-17-0915
Dana-Farber Cancer Institute news release (click here)
RSS Feed
